Pieris Pharmaceuticals, Inc.
Symbool: PIRS
NASDAQ
11.08
USDMarktprijs vandaag
-0.5788
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
13.70M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Pieris Pharmaceuticals, Inc. (PIRS) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 174.43 | 26.4 | 59.2 | 117.8 | |||||||||||
balance-sheet.row.short-term-investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.net-receivables | 11.07 | 6 | 5.8 | 3.3 | |||||||||||
balance-sheet.row.inventory | 2.1 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 37.14 | 6.3 | 8.4 | 6.5 | |||||||||||
balance-sheet.row.total-current-assets | 224.75 | 38.7 | 73.4 | 127.6 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 42.47 | 0 | 20.7 | 23 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0.65 | 0 | 1.4 | 2.9 | |||||||||||
balance-sheet.row.total-non-current-assets | 43.11 | 0 | 22.1 | 25.9 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.account-payables | 22.5 | 3.4 | 4.2 | 8.6 | |||||||||||
balance-sheet.row.short-term-debt | 14.09 | 0 | 0.9 | 1 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 24.12 | 0 | 12.2 | 13.8 | |||||||||||
Deferred Revenue Non Current | 12.49 | 0 | 18.7 | 38.4 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | -12.49 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 36.07 | 8.6 | 10.7 | 15.8 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 36.6 | 0 | 31 | 52.2 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 37.32 | 0 | 12.2 | 13.8 | |||||||||||
balance-sheet.row.total-liab | 154.63 | 11.9 | 67.6 | 102.8 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.37 | 0.1 | 0.1 | 0.1 | |||||||||||
balance-sheet.row.retained-earnings | -1228.58 | -315 | -290.4 | -257.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.87 | 0 | -0.3 | 0.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 1342.3 | 341.6 | 318.5 | 307 | |||||||||||
balance-sheet.row.total-stockholders-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 267.86 | 38.7 | 95.5 | 153.6 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 113.22 | 26.8 | 27.9 | 50.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 267.86 | - | - | - | |||||||||||
Total Investments | 39.46 | 9 | 20.5 | 0 | |||||||||||
balance-sheet.row.total-debt | 37.32 | 0 | 13.1 | 13.8 | |||||||||||
balance-sheet.row.net-debt | -97.65 | -17.4 | -25.5 | -103.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
cash-flows.row.depreciation-and-amortization | 1.81 | 1.8 | 2.8 | 2.4 | |||||||||||
cash-flows.row.deferred-income-tax | 14.53 | -4.5 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 3.35 | 3.3 | 4.4 | 5.2 | |||||||||||
cash-flows.row.change-in-working-capital | -48.14 | -48.1 | -33.4 | 30.5 | |||||||||||
cash-flows.row.account-receivables | 5.31 | 5.3 | -2.6 | -1.8 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 5.7 | |||||||||||
cash-flows.row.account-payables | -0.79 | -0.8 | -4.2 | 7 | |||||||||||
cash-flows.row.other-working-capital | -12.71 | -52.7 | -26.5 | 19.6 | |||||||||||
cash-flows.row.other-non-cash-items | -0.82 | 18.3 | -0.5 | 0 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -53.82 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.acquisitions-net | -12.17 | 0 | 20.2 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | -22.84 | -22.8 | -48.4 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 35.01 | 35 | 28.2 | 0 | |||||||||||
cash-flows.row.other-investing-activites | 12.17 | 0 | -20.2 | 0 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 12 | 12 | -21.2 | -0.9 | |||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -1 | 0 | |||||||||||
cash-flows.row.common-stock-issued | 19.74 | 19.8 | 6.9 | 57.1 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 0.07 | 0.1 | 1.3 | 2 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 19.8 | 19.8 | 7.2 | 59.1 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.78 | 0.8 | -5.2 | -3.2 | |||||||||||
cash-flows.row.net-change-in-cash | -21.24 | -21.2 | -79.1 | 47.3 | |||||||||||
cash-flows.row.cash-at-end-of-period | 134.97 | 17.4 | 38.6 | 117.8 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 156.21 | 38.6 | 117.8 | 70.4 | |||||||||||
cash-flows.row.operating-cash-flow | -53.82 | -53.8 | -59.9 | -7.7 | |||||||||||
cash-flows.row.capital-expenditure | -0.17 | -0.2 | -1 | -0.9 | |||||||||||
cash-flows.row.free-cash-flow | -53.99 | -54 | -61 | -8.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 42.81 | 42.8 | 25.9 | 31.4 | |||||||||||
income-statement-row.row.cost-of-revenue | 6.49 | 1.8 | 2.8 | 2.4 | |||||||||||
income-statement-row.row.gross-profit | 36.32 | 41 | 23.1 | 29.1 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 41.8 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 16.85 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.operating-expenses | 55.04 | 56.9 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.cost-and-expenses | 55.04 | 58.7 | 61.2 | 79.6 | |||||||||||
income-statement-row.row.interest-income | 1.85 | 1.9 | 0.7 | 0 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 13.91 | 13.9 | -8.2 | -3.7 | |||||||||||
income-statement-row.row.total-operating-expenses | -11.32 | -8.7 | 10.2 | 6.1 | |||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -10.2 | 0 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 3.94 | 1.8 | 8.2 | 3.7 | |||||||||||
income-statement-row.row.ebitda-caps | 3.87 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -30.74 | -15.8 | -43.5 | -51.8 | |||||||||||
income-statement-row.row.income-before-tax | -24.54 | -24.5 | -33.3 | -45.7 | |||||||||||
income-statement-row.row.income-tax-expense | 12.28 | 0 | -2 | -2.4 | |||||||||||
income-statement-row.row.net-income | -23.67 | -24.5 | -31.3 | -43.4 |
Vaak gestelde vragen
Wat is Pieris Pharmaceuticals, Inc. (PIRS) totale activa?
Pieris Pharmaceuticals, Inc. (PIRS) totale activa is 38680000.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 20819000.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.848.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.553.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.718.
Wat is Pieris Pharmaceuticals, Inc. (PIRS) nettowinst (netto-inkomen)?
De nettowinst is -24543000.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 0.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 56873000.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 17396000.000.